Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
With a market cap of 66.67B, Regeneron(REGN) trades at $635.94. The stock has a price-to-earnings ratio of 15.66 and currently yields dividends of 55.7%.
As of 2026-05-22, Regeneron(REGN) stock has fluctuated between $632.38 and $644.12. The current price stands at $635.94, placing the stock +0.6% above today's low and -1.3% off the high.
Regeneron(REGN) shares are trading with a volume of 434.96K, against a daily average of 1.18M.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
REGN News
...
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Lam Research Corp (Symbol: LRCX) has taken over the...
Soon after reaching a research pact worth up to $2.3B with Regeneron (REGN), clinical-stage biopharma Parabilis Medicines (PBLS) has submitted regulatory filing...
Analyst ratings
74%
of 31 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sh...
Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $875 from $1,057 and keeps a Buy rating on the shares. The firm updated its...
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported that its Phase 3 trial of fianlimab plus cemiplimab in advanced melanoma did not meet its primary endpoint....
...
Wolfe Research analyst Alexandria Hammond lowered the firm’s price target on Regeneron (REGN) to $860 from $900 and keeps an Outperform rating on the shares. Th...
In early trading on Monday, shares of Thomson Reuters topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.8%. Year to...
In early trading on Monday, shares of Dominion Energy topped the list of the day's best performing components of the S&P 500 index, trading up 11.6%. Year to da...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.